STOCK TITAN

Gilead's Ambition: To Help End the HIV Epidemic

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Gilead Sciences, Inc. (GILD) aims to end the HIV epidemic globally through community partnerships and innovative medicines. The company collaborates with organizations like GNP+, UNAIDS, and PEPFAR to expand access to care in low- and middle-income countries. Gilead operates in over 35 countries and is headquartered in Foster City, California.
Positive
  • None.
Negative
  • None.

NORTHAMPTON, MA / ACCESSWIRE / November 28, 2023 / "At Gilead, we have a bold ambition: We'd like to help end the HIV epidemic for everyone, everywhere and we know you cannot do that alone," shared Janet Dorling, Senior Vice President, Intercontinental Region and Global Patient Solutions.

Through our community partnerships in low- and middle-income countries, we are working together to expand access and reduce barriers to care while embracing innovation.

The panel discussion at the recent World Health Summit also featured leaders from The Global Network of People Living with HIV (GNP+), UNAIDS and PEPFAR.

Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

Originally published by Gilead Sciences

View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Contact Info:
Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: info@3blmedia.com

SOURCE: Gilead Sciences



View source version on accesswire.com:
https://www.accesswire.com/810733/gileads-ambition-to-help-end-the-hiv-epidemic

Gilead aims to help end the HIV epidemic globally through community partnerships and innovative medicines.

Gilead is working to expand access and reduce barriers to care through community partnerships in low- and middle-income countries.

Gilead has partnered with organizations like The Global Network of People Living with HIV (GNP+), UNAIDS, and PEPFAR.

Gilead Sciences, Inc. is headquartered in Foster City, California.

Gilead operates in over 35 countries worldwide.
Gilead Sciences, Inc.

NASDAQ:GILD

GILD Rankings

GILD Latest News

GILD Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
US
Foster City

About GILD

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.